Agios Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 67 to 79.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains tend to have an RS Rating of over 80 in the early stages of their moves. See if Agios Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
While the stock is not near an ideal buy point right now, see if it is able to form and break out from a proper chart pattern.
Agios Pharmaceuticals posted 0% EPS growth last quarter, while sales growth came in at 7%. The company is expected to report its latest performance numbers on or around Jul. 31.
Agios Pharmaceuticals earns the No. 148 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
